Co-occurrence of brain tumours and demyelination of the central nervous system: coincidence or interrelation?
ABSTRACT The co-occurrence of a brain tumour and demyelinating disease of the central nervous system (CNS) constitutes a rare clinical entity. We herein report the incidence of meningioma and CNS non-specific demyelination in a patient with a 6-year history of operated brain tumour (meningioma). Our case bolsters the argument that in at least some cases, the occurrence of a brain tumour could predispose to CNS non-specific demyelination.
- SourceAvailable from: bmj.com[Show abstract] [Hide abstract]
ABSTRACT: Cranial MRI showed multiple lesions in white matter that were thought to be consistent with multiple sclerosis in two young adults presenting with symptoms of progressive myelopathy. MRI of the cervicothoracic spine around one and two years after onset showed the myelopathy to be due to mid-thoracic tumours. The tumours (an extradural meningioma and intradural neuroma) were resected with complete resolution of myelopathy in one patient but no recovery in the other. Spinal MRI (or myelography) should be performed in young patients presenting with signs of progressive myelopathy even when cranial MRI shows a picture typical of multiple sclerosis.Journal of Neurology Neurosurgery & Psychiatry 04/1992; 55(3):216-8. DOI:10.1136/jnnp.55.3.216 · 5.58 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The humoral response of 39 meningioma patients to possible tumourassociated antigens was studied by means of an antibody dependent cell mediated cytotoxicity test (ADCC). Five patients were found to have cytotoxic antibodies against 1 to 10 meningioma cell lines. However, three of these were also cytotoxic against malignant glioma cell lines but not against other unrelated tumours. These results suggest the existence of surface antigens common to meningiomas and gliomas.Acta Neurochirurgica 02/1980; 52(1-2):19-25. DOI:10.1007/BF01400942 · 1.79 Impact Factor
- Annals of Neurology 03/1983; 13(3):227-31. DOI:10.1002/ana.410130302 · 11.91 Impact Factor